NOVAVAX INC (NVV1.DE) Stock Price, Quote, News and Overview
FRA:NVV1 - Deutsche Boerse Ag - US6700024010 - Common Stock - Currency: EUR
NVV1.DE Quote, Performance and Key Statistics
NOVAVAX INC
FRA:NVV1 (2/4/2025, 7:00:00 PM)
8.105
-0.11 (-1.3%)
The current stock price of NVV1.DE is 8.105 EUR. In the past month the price decreased by -9.74%.
NVV1.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.78B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| 0QF.DE | MODERNA INC | N/A | 12.78B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.98 | 1.44B |
Related stock screener links
About NVV1.DE
Company Profile
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 1,543 full-time employees. The firm offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. The company has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The firm is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Company Info
NOVAVAX INC
700 Quince Orchard Road
Gaithersburg MARYLAND US
Employees: 1543
Company Website: https://www.novavax.com/?locale=US
Investor Relations: https://ir.novavax.com/
Phone: 12402682000
NVV1.DE FAQ
What is the stock price of NVV1.DE?
The current stock price of NVV1.DE is 8.105 EUR.
What is the symbol for NOVAVAX INC stock?
The exchange symbol of NOVAVAX INC is NVV1 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is NVV1.DE stock listed?
NVV1.DE stock is listed on the Deutsche Boerse Ag exchange.
Is NVV1.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NVV1.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NVV1.DE.
Does NVV1.DE stock pay dividends?
NVV1.DE does not pay a dividend.
What is the Price/Earnings (PE) ratio of NVV1.DE?
NVV1.DE does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.19).
NVV1.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NVV1.DE.
NVV1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NVV1.DE. Both the profitability and financial health of NVV1.DE have multiple concerns.
NVV1.DE Financial Highlights
Over the last trailing twelve months NVV1.DE reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by 64.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NVV1.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to NVV1.DE. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 76.48% and a revenue growth -28.64% for NVV1.DE